PLAINSBORO, N.J., Jul 27, 2007 (PrimeNewswire via COMTEX News Network) --

XKnife(TM) radiosurgery users presented their latest advances in the treatment of brain, spine and lung tumors on Sunday, July 22 at the 49th annual meeting of the American Association of Physicists in Medicine in Minneapolis, Minnesota. The XKnife(TM) radiosurgery system is developed, manufactured, and marketed by Integra Radionics, a subsidiary of Integra LifeSciences Holdings Corporation (Nasdaq:IART).

Dr. Satish Jaywant, Associate Professor of Radiation Oncology at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, presented his latest work using stereotactic immobilization, cone beam CT, and the Integra Radionics ImageFusion(TM) software algorithms to achieve stereotactic accuracy for extracranial targets. Targets in the cervical, thoracic and lumbar spine, as well as the lung, were treated with the noninvasive XKnife(TM) Body Localizer.

Dr. Lu Wang, Assistant Professor of the Fox Chase Cancer Center in Philadelphia, Pennsylvania, demonstrated the use of 4D CT images, taken inside the simulation room, to account for target motion in lung tumors. 4D CT involves taking multiple images, over time, of the same location in the body so that the tumor's extreme and average positions can be factored into the treatment plan to ensure adequate radiation coverage. Fox Chase has used the XKnife(TM) RT planning software, XKnife(TM) MMLC beam shaper and XKnife(TM) Body Localizer, in conjunction with CT image guidance, to treat over 30 patients with spine, lung and liver cancer.

Dr. Jimm Grimm from Christiana Care Health Services in Newark, Delaware, presented a novel method of improving the accuracy of XKnife(TM) cranial radiosurgery to 0.2mm on most linear accelerators. Dr. Grimm's SAlinac system uses automatic film test analysis and video registration of laser alignment, together with a wireless handheld device which provides real-time realignment advice as necessary. The SAlinac system is not yet available for sale and was presented as a work in progress.

"I am pleased to see the advances our customers are making to target tumors throughout the body utilizing the Integra XKnife(TM) system," says Christopher von Jako, general manager of Integra Radionics. "There is tremendous potential in applying the techniques we have learned from years of treating brain tumors to reduce complications and improve results for tumors in the lung and spine."

Unlike conventional surgery, XKnife(TM) radiosurgery is completely noninvasive and does not require a surgical incision. This eliminates the discomfort and complications associated with standard surgery. Cancerous or other diseased tissue can be treated with focused radiation beams from a linear accelerator (linac) that are precisely guided using computer tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) images. Surrounding normal tissue is spared and patients are typically able to leave the hospital immediately after their approximate thirty minute single treatment. To date, over 45,000 patients have undergone XKnife(TM) radiosurgery.

Integra Radionics products are currently sold in the United States through the Integra NeuroSciences sales organization. Integra NeuroSciences is a leading provider of implants, devices, instruments, and systems used in neurosurgery. Integra NeuroSciences' direct selling effort in North America and Europe currently involves more than 150 professionals. In other markets, Integra NeuroSciences products are sold through a network of distributors.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra LifeSciences products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the "Risk Factors" included in Item lA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.

IART-P

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
          John B. Henneman, III, Executive Vice President
           Chief Administrative Officer
            (609) 936-2481
            jhenneman@Integra-LS.com
          Gianna Sabella, Public Relations Manager
            (609) 936-2389
            gsabella@Integra-LS.com

(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.

News Provided by COMTEX